Format

Send to

Choose Destination
Pediatr Blood Cancer. 2014 Dec;61(12):2307-9. doi: 10.1002/pbc.25102. Epub 2014 Jun 17.

Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.

Author information

1
Department of Pediatrics, Columbia University Medical Center, New York, NY.

Abstract

Allogenic hematopoietic cell transplantation (alloHCT) is currently the only curative treatment option for patients with sickle cell disease. Alemtuzumab is a monoclonal antibody directed against CD52 positive cells used in myeloablative conditioning regimens for alloHCT. Its use has been associated with development of autoimmune disease in adult patients with rheumatologic conditions. We report on three cases of new onset autoimmune thyroid disease after alloHCT treatment with alemtuzumab in pediatric patients with sickle cell disease.

KEYWORDS:

alemtuzumab; autoimmunity; sickle cell disease; stem cell transplant; thyroid dysfunction

PMID:
24938636
PMCID:
PMC4440678
DOI:
10.1002/pbc.25102
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center